Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, September 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has submitted a supplemental new drug application for...
TOKYO (August 30, 2017) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters,...
Read more about Repatha® Receives Approval for New 420mg Single-Dose Delivery Option in Japan
TOKYO – August 22, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the first patient was dosed in the registrational Phase 3...
(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, August 1, 2017- Astellas Pharma Inc. (TSE: 4503, President and CEO:...
Read more about Astellas Announces Status of Acquisition of Own Shares
Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Pharma Inc....
Tokyo, July 31, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has submitted an application for marketing approval of...
TOKYO, July 27, 2017 — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that it is winding down its Agensys research operations in Santa...
Read more about Astellas Announces Wind-Down of Agensys Research Operations
TOKYO – July 20, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) granted...
Osaka and Tokyo (Japan), July 7, 2017 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo,...
Tokyo, July 5, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year to be included in the...
Read more about Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year
Tokyo, June 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the submission of a supplemental New Drug Application (sNDA) to the...
TOKYO – June 20, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the launch of the second year of the Astellas C³ Prize, a...
TOKYO and NEW YORK, June 9, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today the amendment of the protocol...
Kyoto and Tokyo, June 5, 2017 - Kyoto University (President: Juichi Yamagiwa) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the inauguration of...
Tokyo, June 1, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, ”Astellas”) today announced that it has committed to supporting the Global Health Innovative Technology Fund...
Read more about Astellas Announces Commitments to GHIT Fund Replenishment
Tokyo, May 31, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the launch of a new global website. In accordance with the company Disclosure...
Read more about Astellas Announces New Global Website Launch
Tokyo, May 23, 2017 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) on International Day to End Obstetric Fistula, Astellas pledges its support to the Fistula...
Read more about ACTION ON FISTULA TO TRANSFORM 4,500 LIVES BY 2020
Tokyo, May 19, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that MSD has submitted an...
TOKYO – May 17, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today an update regarding the Company’s diverse oncology portfolio,...
Read more about Astellas Announces Oncology Portfolio Updates
Tokyo, May 17, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has completed the acquisition of Ogeda SA (formerly named...
Tokyo, May 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the discontinuation of ASP8273 treatment arm in the the late-stage...
Tokyo, May 11, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko...
Follow us
